These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 27995876)

  • 41. [Expression of EVI1 in Bone Marrow of Patients with AML and ALL and Its Correlation with Leukemia Subtyping, Clinical Features and Prognosis of Patients].
    Peng DH; Liu J; Hu HN
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1323-1329. PubMed ID: 30295245
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia.
    Tanaka A; Nakano TA; Nomura M; Yamazaki H; Bewersdorf JP; Mulet-Lazaro R; Hogg S; Liu B; Penson A; Yokoyama A; Zang W; Havermans M; Koizumi M; Hayashi Y; Cho H; Kanai A; Lee SC; Xiao M; Koike Y; Zhang Y; Fukumoto M; Aoyama Y; Konuma T; Kunimoto H; Inaba T; Nakajima H; Honda H; Kawamoto H; Delwel R; Abdel-Wahab O; Inoue D
    Blood; 2022 Aug; 140(8):875-888. PubMed ID: 35709354
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Aberrant ecotropic viral integration site-1 (EVI-1) and myocyte enhancer factor 2 C gene (MEF2C) in adult acute myeloid leukemia are associated with adverse t (9:22) & 11q23 rearrangements.
    Menshawy NE; El-Ghonemy MS; Ebrahim MA; Fahmi MW; Saif M; Denewer M; El-Ashwah S
    Ann Hematol; 2024 Jul; 103(7):2355-2364. PubMed ID: 38710877
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Clinical significance of expressions of EVI1 and BRE genes in 47 acute leukemia patients with MLL rearrangement].
    Gong YL; Zhang JR; Zhang J; Bai SX; Cen JN; Shen HJ; Chou HY; Chen SN; Pan JL
    Zhonghua Xue Ye Xue Za Zhi; 2017 Jan; 38(1):22-27. PubMed ID: 28219220
    [No Abstract]   [Full Text] [Related]  

  • 45. [The role of SF3B1 mutations in EVI1-rearranged myeloid neoplasms].
    Tanaka A
    Rinsho Ketsueki; 2023; 64(10):1258-1265. PubMed ID: 37914237
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 3q26/EVI1 rearrangements in myeloid hemopathies: a cytogenetic review.
    De Braekeleer M; Le Bris MJ; De Braekeleer E; Basinko A; Morel F; Douet-Guilbert N
    Future Oncol; 2015; 11(11):1675-86. PubMed ID: 26043219
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis.
    Hu Z; Hu S; Ji C; Tang Z; Thakral B; Loghavi S; Medeiros LJ; Wang W
    Leuk Res; 2018 Feb; 65():25-28. PubMed ID: 29288910
    [TBL] [Abstract][Full Text] [Related]  

  • 48. P-glycoprotein and multidrug resistance associated protein-1 activity in 132 acute myeloid leukemias according to FAB subtypes and cytogenetics risk groups.
    Legrand O; Zompi S; Perrot JY; Faussat AM; Benderra Z; Chaoui D; Marie JP
    Haematologica; 2004 Jan; 89(1):34-41. PubMed ID: 14754604
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Acute panmyelosis with myelofibrosis with EVI1 amplification.
    Grygalewicz B; Woroniecka R; Pastwińska A; Rygier J; Krawczyk P; Borg K; Makuch-Łasica H; Patkowska E; Pieńkowska-Grela B
    Cancer Genet; 2012 May; 205(5):255-60. PubMed ID: 22682625
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups.
    Creutzig U; Zimmermann M; Reinhardt D; Rasche M; von Neuhoff C; Alpermann T; Dworzak M; Perglerová K; Zemanova Z; Tchinda J; Bradtke J; Thiede C; Haferlach C
    Cancer; 2016 Dec; 122(24):3821-3830. PubMed ID: 27529519
    [TBL] [Abstract][Full Text] [Related]  

  • 51. EVI1 overexpression is a poor prognostic factor in pediatric patients with mixed lineage leukemia-AF9 rearranged acute myeloid leukemia.
    Matsuo H; Kajihara M; Tomizawa D; Watanabe T; Saito AM; Fujimoto J; Horibe K; Kodama K; Tokumasu M; Itoh H; Nakayama H; Kinoshita A; Taga T; Tawa A; Taki T; Shiba N; Ohki K; Hayashi Y; Yamashita Y; Shimada A; Tanaka S; Adachi S
    Haematologica; 2014 Nov; 99(11):e225-7. PubMed ID: 25015941
    [No Abstract]   [Full Text] [Related]  

  • 52. [Molecular mechanisms in the development of acute myeloid leukemia].
    Ichikawa M; Kurokawa M
    Nihon Rinsho; 2009 Oct; 67(10):1889-93. PubMed ID: 19860185
    [TBL] [Abstract][Full Text] [Related]  

  • 53. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.
    Gaidzik VI; Bullinger L; Schlenk RF; Zimmermann AS; Röck J; Paschka P; Corbacioglu A; Krauter J; Schlegelberger B; Ganser A; Späth D; Kündgen A; Schmidt-Wolf IG; Götze K; Nachbaur D; Pfreundschuh M; Horst HA; Döhner H; Döhner K
    J Clin Oncol; 2011 Apr; 29(10):1364-72. PubMed ID: 21343560
    [TBL] [Abstract][Full Text] [Related]  

  • 54. AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases.
    Schoch C; Schnittger S; Klaus M; Kern W; Hiddemann W; Haferlach T
    Blood; 2003 Oct; 102(7):2395-402. PubMed ID: 12805060
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Correlation of immunophenotype to cytogenetics and clinical features of adult acute myeloid leukemia].
    Wang XB; Zheng JE; Gu JX; Yao JX; Yang J; Liu J; Li XQ; He YL; Yu JM; Wei J; Liu ZP; Huang SA
    Ai Zheng; 2005 Jun; 24(6):667-71. PubMed ID: 15946475
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A murine model of acute myeloid leukemia with Evi1 overexpression and autocrine stimulation by an intracellular form of GM-CSF in DA-3 cells.
    Cardona ME; Simonson OE; Oprea II; Moreno PM; Silva-Lara MF; Mohamed AJ; Christensson B; Gahrton G; Dilber MS; Smith CI; Arteaga HJ
    Leuk Lymphoma; 2016; 57(1):183-92. PubMed ID: 25907616
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Induction of the proapoptotic tumor suppressor gene Cell Adhesion Molecule 1 by chemotherapeutic agents is repressed in therapy resistant acute myeloid leukemia.
    Fisser MC; Rommer A; Steinleitner K; Heller G; Herbst F; Wiese M; Glimm H; Sill H; Wieser R
    Mol Carcinog; 2015 Dec; 54(12):1815-9. PubMed ID: 25491945
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Clinical and cytogenetics studies on acute myeloid leukemia with abnormality of chromosome 11].
    Lu Y; Xu W; Chen Z; Lou J; Jin J
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Oct; 25(5):583-5. PubMed ID: 18841578
    [TBL] [Abstract][Full Text] [Related]  

  • 59. EVI1-rearranged acute myeloid leukemias are characterized by distinct molecular alterations.
    Lavallée VP; Gendron P; Lemieux S; D'Angelo G; Hébert J; Sauvageau G
    Blood; 2015 Jan; 125(1):140-3. PubMed ID: 25331116
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression.
    Birdwell CE; Fiskus W; Kadia TM; Mill CP; Sasaki K; Daver N; DiNardo CD; Pemmaraju N; Borthakur G; Davis JA; Das K; Sharma S; Horrigan S; Ruan X; Su X; Khoury JD; Kantarjian H; Bhalla KN
    Leukemia; 2024 Mar; 38(3):545-556. PubMed ID: 38086946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.